Kamran Alam

2022 - Taysha Gene Therapies

In 2022, Kamran Alam earned a total compensation of $1.2M as Chief Financial Officer at Taysha Gene Therapies, a 34% decrease compared to previous year.

Compensation breakdown

Bonus$156,000
Non-Equity Incentive Plan$136,578
Option Awards$498,215
Salary$401,700
Other$9,330
Total$1,201,823

Alam received $498.2K in option awards, accounting for 41% of the total pay in 2022.

Alam also received $156K in bonus, $136.6K in non-equity incentive plan, $401.7K in salary and $9.3K in other compensation.

Rankings

In 2022, Kamran Alam's compensation ranked 2,671st out of 5,753 executives tracked by ExecPay. In other words, Alam earned more than 53.6% of executives.

ClassificationRankingPercentile
All
2,671
out of 5,753
54th
Division
Manufacturing
1,488
out of 3,133
53rd
Major group
Chemicals And Allied Products
684
out of 1,419
52nd
Industry group
Drugs
637
out of 1,320
52nd
Industry
Biological Products, Except Diagnostic Substances
156
out of 291
46th
Source: SEC filing on May 8, 2023.

Alam's colleagues

We found three more compensation records of executives who worked with Kamran Alam at Taysha Gene Therapies in 2022.

2022

RA Session

Taysha Gene Therapies

Chief Executive Officer

2022

Sean Nolan

Taysha Gene Therapies

Chief Executive Officer

2022

Sukumar Nagendran

Taysha Gene Therapies

President and Head of Research and Development

News

You may also like